A Systematic Review of Patients' and Providers' Perspectives of Medications for Treatment of Opioid Use Disorder

Overview

Journal J Subst Abuse Treat

Specialty Psychiatry

Date 2020 Nov 3

PMID 33138929

Citations 60

Authors

Katharine Cioe

Breanne E Biondi

Rebecca Easly

Amanda Simard

Xiao Zheng

Sandra A Springer

Affiliations

Soon will be listed here.

Abstract

Background: The opioid epidemic is a public health crisis. Medications for opioid use disorder (MOUD) include: 1) buprenorphine, 2) methadone, and 3) extended-release naltrexone (XR-NTX). Research should investigate patients' and providers' perspectives of MOUD since they can influence prescription, retention, and recovery.

Methods: This systematic review focused on patients' and providers' perceptions of MOUD. The review eligibility criteria included inclusion of the outcome of interest, in English, and involving persons ≥18 years. A PubMed database search yielded 1692 results; we included 152 articles in the final review.

Results: There were 63 articles about buprenorphine, 115 articles about methadone, and 16 about naltrexone. Misinformation and stigma associated with MOUD were common patient themes. Providers reported lack of training and resources as barriers to MOUD.

Conclusion: This review suggests that patients have significant misinformation regarding MOUD. Due to the severity of the opioid epidemic, research must consider the effects of patients' and providers' perspectives on treatment for OUD, including the effects on the type of MOUD prescribed, patient retention and adherence, and ultimately the number of patients treated for OUD, which will aid in curbing the opioid epidemic.

Citing Articles

Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting.

Burke A, Vadiei N, Mollon L Drug Alcohol Depend Rep. 2025; 13:100292.

PMID: 39764386 PMC: 11701998. DOI: 10.1016/j.dadr.2024.100292.

Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine.

Machavariani E, Bromberg D, Dumchev K, Esserman D, Earnshaw V, Pykalo I Int J Drug Policy. 2024; 136:104682.

PMID: 39705875 PMC: 11821433. DOI: 10.1016/j.drugpo.2024.104682.

"Bupe by the Book": A study protocol for a pilot randomized controlled trial of library-facilitated telehealth to increase buprenorphine treatment among unstably housed individuals.

Urada L, Marienfeld C, Partch M, Garfein R, Strathdee S, Nicholls M Res Sq. 2024; .

PMID: 39649172 PMC: 11623763. DOI: 10.21203/rs.3.rs-5507141/v1.

Differential Effects of Prenatal Buprenorphine and Methadone on Postnatal Growth and Gene Expression in the Nucleus Accumbens.

Gildawie K, Budge K, Vassoler F, Yen E, Byrnes E Dev Psychobiol. 2024; 67(1):e70015.

PMID: 39648276 PMC: 11709121. DOI: 10.1002/dev.70015.

Methadone clinic staff perceptions of trauma-informed and patient-centered care: the role of individual staff characteristics.

Meyerson B, Linde-Krieger L, Carter G, Huff A, Brady B, Crosby R Addict Sci Clin Pract. 2024; 19(1):87.

PMID: 39616394 PMC: 11608490. DOI: 10.1186/s13722-024-00501-6.

References

ROSENBLUM A, Magura S, Joseph H . Ambivalence toward methadone treatment among intravenous drug users. J Psychoactive Drugs. 1991; 23(1):21-7. DOI: 10.1080/02791072.1991.10472571. View

Bazazi A, Yokell M, Fu J, Rich J, Zaller N . Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011; 5(3):175-80. PMC: 3157053. DOI: 10.1097/ADM.0b013e3182034e31. View

Newman R . Methadone maintenance: it ain't what it used to be. Br J Addict Alcohol Other Drugs. 1976; 71(2):183-6. DOI: 10.1111/j.1360-0443.1976.tb00077.x. View

Alanis-Hirsch K, Croff R, Ford 2nd J, Johnson K, Chalk M, Schmidt L . Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. J Subst Abuse Treat. 2015; 62:68-73. PMC: 4724460. DOI: 10.1016/j.jsat.2015.10.003. View

Komaromy M, Duhigg D, Metcalf A, Carlson C, Kalishman S, Hayes L . Project ECHO (Extension for Community Healthcare Outcomes): A new model for educating primary care providers about treatment of substance use disorders. Subst Abus. 2016; 37(1):20-4. PMC: 4873719. DOI: 10.1080/08897077.2015.1129388. View

Fischer B, Cape D, Daniel N, Gliksman L . Methadone treatment in Ontario after the 1996 regulation reforms. Results of a physician survey. Ann Med Interne (Paris). 2003; 153(7 Suppl):2S11-21. View

Gu J, Xu H, Lau J, Hao Y, Zhong Y, Fan L . Misconceptions predict dropout and poor adherence prospectively among newly admitted first-time methadone maintenance treatment clients in Guangzhou, China. Addiction. 2012; 107(9):1641-9. DOI: 10.1111/j.1360-0443.2012.03859.x. View

Klingemann J . The rights of drug treatment patients: Experience of addiction treatment in Poland from a human rights perspective. Int J Drug Policy. 2017; 43:67-73. DOI: 10.1016/j.drugpo.2017.01.015. View

Frank D . "I Was Not Sick and I Didn't Need to Recover": Methadone Maintenance Treatment (MMT) as a Refuge from Criminalization. Subst Use Misuse. 2017; 53(2):311-322. PMC: 6088379. DOI: 10.1080/10826084.2017.1310247. View

10.

Larney S, Zador D, Sindicich N, Dolan K . A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev. 2016; 36(3):305-310. DOI: 10.1111/dar.12442. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

12.

Sohler N, Weiss L, Egan J, Lopez C, Favaro J, Cordero R . Consumer attitudes about opioid addiction treatment: a focus group study in New York City. J Opioid Manag. 2013; 9(2):111-9. PMC: 4012752. DOI: 10.5055/jom.2013.0152. View

13.

Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L . Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug Alcohol Depend. 2017; 179:213-219. PMC: 5599372. DOI: 10.1016/j.drugalcdep.2017.07.010. View

14.

Schuman-Olivier Z, Connery H, Griffin M, Wyatt S, Wartenberg A, Borodovsky J . Clinician beliefs and attitudes about buprenorphine/naloxone diversion. Am J Addict. 2013; 22(6):574-80. PMC: 3801272. DOI: 10.1111/j.1521-0391.2013.12024.x. View

15.

Caplehorn J, Irwig L, Saunders J . Attitudes and beliefs of staff working in methadone maintenance clinics. Subst Use Misuse. 1996; 31(4):437-52. DOI: 10.3109/10826089609045820. View

16.

FRAM D, Marmo J, Holden R . Naltrexone treatment--the problem of patient acceptance. J Subst Abuse Treat. 1989; 6(2):119-22. DOI: 10.1016/0740-5472(89)90039-1. View

17.

Singleton E, Sherman M, Bigelow G . The index of choice: indications of methadone patients' selection of naltrexone treatment. Am J Drug Alcohol Abuse. 1984; 10(2):209-21. DOI: 10.3109/00952998409002781. View

18.

Loxterkamp D . Medication-Assisted Treatment Should Be Part of Every Family Physician's Practice: Yes. Ann Fam Med. 2017; 15(4):309-310. PMC: 5505447. DOI: 10.1370/afm.2103. View

19.

Abraham A, Andrews C, Harris S, Friedmann P . Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics. 2020; 17(1):55-69. PMC: 7007488. DOI: 10.1007/s13311-019-00814-4. View

20.

Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi A . A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. Int J Drug Policy. 2009; 21(3):167-72. DOI: 10.1016/j.drugpo.2009.03.001. View